Table 2.
In vivo effects of CsA on different non-autologous cell types, compared to control
| Reference | Cell type | Animal model | N | CsA dosage (mg/kg/day) |
Administration | Conclusion |
|---|---|---|---|---|---|---|
| Positive effect | ||||||
| Guo et al. [61] | Human SkM | Rat | 208 | 10 | Intraperitoneal | Reduced immunocyte infiltration, enhanced cell survival, improved EF |
| Westrich et al. [62] | Rat MSC | Rat | 12 | 10 | NA | Enhanced cell survival |
| Negative or neutral effect | ||||||
| Chiavegato et al. [63] | Human AFS | Rat | 42 | 5 | Intramuscular | Unsuccessful inhibition of cell rejection |
| Zeng et al. [64] | Swine pMultistem | Swine | 30 | 15 | Oral | No effect on engraftment and cardiac function |
SkM skeletal myoblasts, MSC mesenchymal stem cells, AFS amniotic fluid-derived stem cells, MNC mononuclear cell, pMultistem bone marrow-derived adherent stem cells, EF ejection fraction